Bristol-Myers Squibb to Present New Data Demonstrating Company's Leadership in Liver Disease at The Liver Meeting(R) //AASLD Annual Meeting

[Guest guest]

http://www.marketwatch.com/story/bristol-myers-squibb-to-present-new-data-demons\

trating-companys-leadership-in-liver-disease-at-the-liver-meetingr-aasld-annual-\

meeting-2011-09-30

press release

Sept. 30, 2011, 11:19 a.m. EDT

Bristol-Myers Squibb to Present New Data Demonstrating Company's Leadership in

Liver Disease at The Liver Meeting® / AASLD Annual Meeting

Oral presentation on BARACLUDE® (entecavir) reinforces continued clinical

development commitment in hepatitis B

PRINCETON, N.J., Sep 30, 2011 (BUSINESS WIRE) -- --Oral presentations on

hepatitis C investigational compounds BMS-790052 and BMS-650032 demonstrate

advancement of robust pipeline

--Breadth of data highlights Company's commitment to pursuing research that aims

to improve the management of liver disease

Bristol-Myers Squibb Company /quotes/zigman/220498/quotes/nls/bmy BMY +0.84%

announced today that 22 abstracts on the Company's research in liver disease

have been accepted for presentation at The Liver Meeting® 2011, the 62nd

annual meeting of the American Association for the Study of Liver Diseases

(AASLD), in San Francisco, November 4 - 8. Bristol-Myers Squibb is advancing a

portfolio of compounds that has the potential to address unmet medical needs for

patients with liver disease, including BARACLUDE® (entecavir) for chronic

hepatitis B (CHB), and the investigational compounds BMS-790052, BMS-650032 and

PEG-Interferon lambda (Lambda) for hepatitis C (HCV) and brivanib for

hepatocellular carcinoma (HCC).

Key presentations include an oral presentation on BARACLUDE monotherapy vs.

combination therapy for CHB and two oral presentations of Phase II data on the

Company's investigational HCV direct-acting antivirals (DAAs). These

presentations will highlight:

-- The first data from the BE-LOW study, a Phase IIIb comparative study of

BARACLUDE plus tenofovir vs. BARACLUDE monotherapy in treatment-naive adults

with CHB

-- The first results from a Phase IIb study of the NS5A replication complex

inhibitor BMS-790052 plus peginterferon alfa and ribavirin (alfa/RBV) in

treatment-naive HCV genotype 1 and 4 patients, evaluating virologic response

through 12 weeks on treatment (eRVR)

-- The first results of a Phase IIa study of the dual DAA regimen of BMS-790052

and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected patients

who have not responded to prior alfa/RBV therapy (null responders), evaluating

sustained virologic response 12 weeks post-treatment (SVR12)

" Bristol-Myers Squibb is at the forefront of innovation in researching the

treatment of liver diseases. In hepatitis C, where there remain considerable

unmet medical needs, our goal is to increase treatment options for patients by

developing a portfolio of compounds with different mechanisms of action, " said

s, MD, senior vice president, Global Development and Medical

Affairs, Research and Development, Bristol-Myers Squibb. " The data we are

presenting at the Liver Meeting help to expand our understanding of the

potential efficacy and safety profiles of these investigational compounds and

support the recent initiation of a broad Phase III development program in HCV. "

The Company will also present new data that further describe the mechanistic and

clinical profile of Lambda, and real-world data that add to the understanding of

the prevalence of and current treatment patterns in HBV, HCV and HCC, including

an oral presentation of data from the BRIDGE study in HCC. The BRIDGE study is

designed to develop global understanding of HCC, including assessment of

treatment by geography and etiology, and associated clinical outcomes.

The complete list of Bristol-Myers Squibb data presentations is located at:

http://www.marketwatch.com/story/bristol-myers-squibb-to-present-new-data-demons\

trating-companys-leadership-in-liver-disease-at-the-liver-meetingr-aasld-annual-\

meeting-2011-09-30

Abstracts can be accessed on the AASLD website at:

http://aasld2011.abstractcentral.com/login

*SEE INDICATION and IMPORTANT SAFETY INFORMATION about BARACLUDE® (entecavir)

AT BOTTOM OF WEB PAGE AT:

http://www.marketwatch.com/story/bristol-myers-squibb-to-present-new-data-demons\

trating-companys-leadership-in-liver-disease-at-the-liver-meetingr-aasld-annual-\

meeting-2011-09-30

SOURCE: Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

Media:

Cristi Barnett, 609-252-6028

cristi.barnett@...

or

Investors:

Elicker, 609-252-4611

john.elicker@...